Understanding Human Papillomavirus: Human Papillomavirus (HPV) is a sexually transmitted infection spread through skin-to-skin contact. Roughly 79 million Americans have HPV, making it the most common STI in the United States.
healtheo360 Wellness Blog
Every year, 1 in every 4 teens contracts an STD/STI. Sexually Transmitted Infections (STIs) Awareness Month offers support, education, and awareness to individuals about sexually transmitted infections.
What is a Sexually Transmitted Infection?
Did you know that more than 12, 000 women in the United States will be diagnosed with Cervical Cancer? Cervical cancer was a major cause of death of women in the US, however this does not mean it’s still not deadly. Cervical Health Awareness Month is to raise awareness about women protecting themselves from HPV and Cervical Cancer.
What is Cervical Cancer?
Did you know that in 2014 that more men (91% cases) than women (9% cases) diagnosed with Syphilis?
Commons STD 1# Chlamydia
January is Cervical Cancer Awareness Month. This month focuses on the prevention of cervical cancer to help eliminate and reduce the prevalence of the disease. Cervical cancer is one of the most preventable kinds of cancers, however 12,000 women in the US are diagnosed each year, with 4,000 women dying from the disease. It is the second most prevalent type of cancer for women in the US, but with proper, early detection it is normally very treatable and preventable.
What is cervical cancer?
This month the FDA approved Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) to be used for vaccination against nine types of the Human Papillomavirus (HPV). This new vaccination will be able to help prevent five more types of HPV than the previous vaccination, and will work to prevent 90% of cervical, vaginal, vulvar, and anal cancers. Although not yet available, the medical community is working on the release of the new vaccine for the near future.
HPV has a variety of types, and the vaccination works to prevent the types that most commonly lead to cancer. This new vaccination protects against types 16, 18, 31, 33, 45, 52 and 58. In the previous vaccine, only 16 and 18 were vaccinated against—and with Gardasil 9 an additional 20% of cervical cancers are now covered.
The Center for Disease Control and Prevention recently released a report indicating that eight million US women have not been tested for cervical cancer in the last 5 years. Screenings and vaccinations are a key component of cervical cancer and HPV prevention, and it is estimated that in 50% of cervical cancer cases the patient did not have regular screenings.
MONDAY, April 14, 2014 (HealthDay News) -- A sharp drop in the number of young women infected with the two strains of human papillomavirus (HPV) most likely to cause cervical cancer occurred in England after the 2008 launch of a national vaccination program there, a new study shows.
Keith Brofsky/Thinkstock(RIO DE JANEIRO) -- Researchers have made great strides in early detection and prevention for cervical cancer, the third-most common cancer in women, including the HPV vaccine. But with all the progress, there are still thousands of women with advanced disease, and the five-year survival rate for late-stage cervical cancer is 15 percent. That number may now climb dramatically, if the results of a trial for Erlotinib, now in its second phase, proves typical.
The standard care for advanced cervical cancer is chemo-radiation and Cisplatin, a nonspecific drug. Erlotinib, the epidermal growth factor receptor (EGFR) inhibitor, is a type of biologic medication targeting growth receptors in the cancerous cells -- they can’t grow and cancer recedes.
For the study, which is published in the journal Cancer, Brazilian researchers at the Instituto de Cancer in Rio de Janeiro conducted a small trial in 36 women with Stage II and III cervical cancer (which now has a survival rate of 40 percent). After 77 weeks of treatment, all but two patients saw a complete disappearance of the cancer. At two and three years out, 92 percent and 80 percent of women survived, respectively.
Side effects of Erlotinib were generally manageable with patients experiencing mostly rashes and diarrhea.
According to the study authors, this is the first study to show that a target agent has promising activity against locally advanced cervical cancer. Still, more research is needed as the data presented in the trial is only preliminary.
Copyright 2014 ABC News Radio